Biosimilars in Australia: biosimilar infliximab – opportunities in management of chronic inflammatory disease – Certificate of Completion

After completing this program, participants will be better able to:

1. Recognise what biosimilars are and describe differences in the Australian regulatory approval process for biosimilars and generics.
2. Describe current issues around biosimilars: extrapolation of indications, interchangeability, naming convention.
3. Appraise the impact of biosimilar infliximab on the management of inflammatory bowel disease, rheumatological disease and psoriasis.
4. Outline issues to consider including relevant safety and efficacy data and prescribing requirements when selecting biosimilar infliximab for patients with inflammatory bowel disease, rheumatological disease and psoriasis.
5. Describe the potential impact of switching from originator infliximab to biosimilar or one biosimilar infliximab to other biosimilar infliximab products.